Loading…
Astonea Labs (BSE 544409)₹335.000.00%Pharmaceuticals
In the Mar 2026 quarter (standalone), Astonea Labs reported sales of ₹80.99 Cr and net profit of ₹3.01 Cr. For the year to Mar 2026, sales were ₹148 Cr and net profit ₹5.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 47.04 | 66.03 | 80.99 |
| Expenses | 41.07 | 61.18 | 73.13 |
| Operating Profit | 7.01 | 5.01 | 8.01 |
| OPM % | 14.0% | 8.0% | 10.0% |
| Other Income | 0.00 | 0.00 | 0.00 |
| Interest | 2.01 | 2.01 | 2.01 |
| Depreciation | 1.99 | 1.99 | 2.99 |
| Profit before tax | 2.99 | 1.99 | 3.99 |
| Tax % | 24.0% | 20.0% | 20.0% |
| Net Profit | 2.01 | 1.01 | 3.01 |
| EPS (Rs) | 2.77 | 1.36 | 2.96 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 30.04 | 67.03 | 80.12 | 98.13 | 148 |
| Expenses | 24.07 | 60.15 | 68.18 | 82.23 | 134 |
| Operating Profit | 6.01 | 7.01 | 12.02 | 15.03 | 14.02 |
| OPM % | 19.0% | 11.0% | 15.0% | 16.1% | 9.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 |
| Interest | 2.01 | 2.01 | 3.01 | 4.01 | 3.01 |
| Depreciation | 3.99 | 3.99 | 3.99 | 4.99 | 4.99 |
| Profit before tax | 0.99 | 0.99 | 4.99 | 6.99 | 5.99 |
| Tax % | 57.0% | 39.0% | 24.0% | 24.0% | 20.0% |
| Exceptional items | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 |
| Net Profit | 0.00 | 1.01 | 4.01 | 5.01 | 5.01 |
| EPS (Rs) | 0.63 | 1.69 | 5.38 | 6.95 | 4.32 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 4.01 | 4.01 | 8.03 | 8.02 | 11.03 |
| Reserves | 2.99 | 3.98 | 3.99 | 10.96 | 46.92 |
| Borrowings | 30.02 | 36.02 | 42.06 | 53.07 | 43.05 |
| Other Liabilities | 16.05 | 20.06 | 26.00 | 32.03 | 46.22 |
| Total Liabilities | 53.07 | 64.07 | 81.08 | 103 | 146 |
| Fixed Assets | 21.03 | 21.03 | 22.07 | 26.05 | 31.08 |
| CWIP | 0.00 | 0.00 | 1.99 | 3.99 | 7.98 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 5.99 |
| Other Assets | 32.04 | 44.04 | 57.02 | 73.04 | 101 |
| Inventories | 6.98 | 16.95 | 24.91 | 28.92 | 33.89 |
| Trade receivables | 18.98 | 18.97 | 24.96 | 37.96 | 51.94 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 53.07 | 64.07 | 81.08 | 103 | 146 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | −5.02 | −1.01 | 8.03 | 9.03 | −14.06 |
| Cash from investing activity | −2.99 | −2.99 | −7.99 | −10.97 | −19.95 |
| Cash from financing activity | 7.98 | 3.99 | 0.00 | 1.99 | 33.89 |
| Net cash flow | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 |
| Capex | 3.32 | 3.11 | 7.44 | 10.78 | 13.96 |
| Free cash flow | −7.98 | −3.99 | 0.00 | −1.99 | −27.92 |
| CFO / OP % | −75.0% | −9.0% | 71.0% | 70.0% | −88.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 234 | 103 | 115 | 141 | 128 |
| Inventory days | 135 | 120 | 160 | 160 | 124 |
| Days payable | 273 | 128 | 149 | 144 | 150 |
| Cash conversion cycle | 98 | 97 | 128 | 159 | 103 |
| Working capital days | 99 | 34 | 29 | 23 | 75 |
| ROCE % | — | 7.9% | 16.9% | 16.9% | 11.0% |
For the Mar 2026 quarter, Astonea Labs reported sales of ₹80.99 Cr and net profit of ₹3.01 Cr. The operating margin was 10.0%.
Astonea Labs' sales for the year to Mar 2026 were ₹148 Cr.
Net profit for the year to Mar 2026 was ₹5.01 Cr. Earnings per share over the same trailing period were ₹4.32.
Astonea Labs reported borrowings of ₹43.05 Cr at Mar 2026, against cash and equivalents of ₹0 Cr.
Cash from operations was −₹14.06 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹27.92 Cr.